Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

2403 PWToday Stories

BioDelivery Sciences Announces Agreement with CVS/Caremark for BELBUCA® and BUNAVAIL® Through 2020

22 Jun 17

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has signed an agreement with CVS/Caremark extending access to both BELBUCA® (buprenorphine) buccal film (CIII) and BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) through 2020.  The agreement is important as CVS/Caremark represents a significant portion of the covered lives in the United States. 

BDSI reacquired BELBUCA from Endo Pharmaceuticals in January 2017 and subsequently relaunched the product.  Prescription sales for BELBUCA reached their highest point in May 2017 since the product was launched by Endo in early 2016 and continues to grow in June.  Weekly sales for BELBUCA for the week ending June 9, 2017 (1,657 prescriptions) exceeded the previous peak from December 2016 for the first time according to data from Symphony Health.

"We are pleased with the momentum we are beginning to see with BELBUCA as well as the execution of new managed care contracts, such as the CVS/Caremark agreement which goes through 2020," said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "We have seen an overall increase in BELBUCA sales since relaunching the product, and for the first time, we recently exceeded both monthly and weekly sales levels achieved by Endo, suggesting that our current strategy, although early in the process, appears to be working as planned.  Furthermore, we believe the continued focus on responsible use of opioids and actions taken by FDA in this regard bode well for BELBUCA's growth prospects." 

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.